Frank Vinluan from MedCity News - Journalist Profile

	Profile	Contacts	Recent Articles on Subject
1	Frank Vinluan MedCity News Medical innovation tracker. MedCity, USA medicalinnovation		FDA Nod Paves Way for AstraZeneca Drug to Become New Standard of Care in Rare Blood Cancer - 4 days ago Galapagos CEO Tells JPM Audience the Rationale for Planned Business Separation - 5 days ago At JPM, Eli Lilly’s CEO Explains Why Mounjaro, Zepbound Sales Were Lower Than Expected - 7 days ago J&J Bolsters Its Prospects in Brain Health With $14B Buyout of Intra-Cellular Therapies - 8 days ago Galapagos Keeps Focus on Cancer Cell Therapy, Spins Out Rest of Biz Into NewCo Backed by €2.4B - 13 days ago Biopharma in 2025: Outlook for Obesity Meds, Drug Prices, Regulation & More - 14 days ago Novo Nordisk Adds Obesity and Diabetes to AI Drug Research Pact With Flagship’s Valo Health - 14 days ago A Startup’s €90M Financing for Oral Peptide Drugs Includes Backing from Eli Lilly - 16 days ago FDA Wraps Up 2024 Handing Out Several Notable Regulatory Decisions - 20 days ago Pfizer Ends Sangamo Alliance With Gene Therapy for Hemophilia on Cusp of FDA Filing - 22 days ago Axsome Aims for FDA Filing in Alzheimer’s Agitation Despite Mixed Bag of Phase 3 Data - 22 days ago Bristol Myers Squibb Wins FDA Nod for Injectable Version of Blockbuster Cancer Drug - 23 days ago The Chase for Novel Oral GLP-1 Obesity Meds Adds a New Contender - 27 days ago Bristol Myers Squibb’s Sotyktu Meets Goals in Two Pivotal Psoriatic Arthritis Studies - 29 days ago Eli Lilly’s Zepbound Becomes First FDA-Approved Drug Therapy for Sleep Apnea - about 1 month ago Startup SiteOne Secures $100M to Forge Ahead With Novel Non-Opioid Pain Meds - about 1 month ago Teva and Sanofi Mid-Stage Data Reveal Shows Best-in-Class Potential for IBD Drug - about 1 month ago Neurocrine Lands FDA Nod for First New Treatment in Decades for Rare Endocrine Disorder - about 1 month ago Novo Nordisk Adds to Manufacturing Capacity, Pumping Billions Into New Rare Disease Site - about 1 month ago ASH 2024 Recap: Movement in Multiple Myeloma, Cell Therapy, Sickle Cell Disease & More - about 1 month ago AI Biotech BenevolentAI Restructures Again, This Time to Return to Its TechBio Roots - about 1 month ago Safety Stands Out in Arcellx Cell Therapy’s ASH Data, But Don’t Overlook Manufacturing Advantages - about 1 month ago GSK Multiple Myeloma Drug’s DREAMM Comeback Continues With Phase 3 Data at ASH - about 1 month ago Safety Signal in Phase 2 Deals a Setback to BioAge Labs’ Muscle-Preserving Obesity Drug - about 1 month ago Nuvig Therapeutics Nabs $161M to Build Case for a Better Approach to Autoimmune Disease - about 2 months ago Eli Lilly’s Zepbound Leads to Greater Weight Loss vs. Novo Nordisk Drug in Head-to-Head Test - about 2 months ago Takeda Pays $200M for Keros Therapeutics Drug With Potential in Blood Cancers and Beyond - about 2 months ago Novartis Tries Again in Huntington’s, Putting Up $1B to Partner on a PTC Therapeutics Drug - about 2 months ago Applied Therapeutics Drug Is Denied FDA Approval in Rare Inherited Metabolic Disease - about 2 months ago Startup OncoSwab Aims to Make Lung Cancer Detection as Simple as Flu & Covid-19 Tests - about 2 months ago Weight Loss With Amgen Drug in Line With Eli Lilly Med, But Dosing Could Be Differentiator - about 2 months ago Roche Expands Its Scope in Allogeneic Cell Therapy With $1B Poseida Therapeutics Acquisition - about 2 months ago FDA Nod for BridgeBio Brings New Competition to Blockbuster Pfizer Cardio Drug - about 2 months ago Halozyme Pulls €2B Acquisition Bid as Evotec Commits to Standalone Strategy - about 2 months ago Patient Dies in Gene Therapy Trial, But FDA Permits Neurogene to Proceed With Low Dose - 2 months ago Kura Oncology Gets $330M to Kick Off Global Leukemia Drug Pact With Kyowa Kirin - 2 months ago Startup Valora Unveils a Sweet Way to Stop Cancer and Autoimmune Disease, Plus $30M for R&D - 2 months ago Merck Gets a Shot of Confidence From Pivotal Test of SubQ Injectable Keytruda - 2 months ago Syndax Pharmaceuticals Leukemia Drug Wins a First-in-Class FDA Approval - 2 months ago GSK Wagers $80M on a Tech Platform and Parkinson’s Drug from Flagship-Founded Vesalius - 2 months ago Halozyme Makes Unsolicited €2B Takeover Bid for Drug R&D Services Firm Evotec - 2 months ago PTC Therapeutics Wins First FDA Approval for a Gene Therapy Dosed Directly Into the Brain - 2 months ago Merck Is Paying $588M for Potential Successor to Cancer Drug Juggernaut Keytruda - 2 months ago Johnson & Johnson Takes the 340B Drug Rebate Fight to Federal Court - 2 months ago AbbVie Drug Expected to Rival Bristol Myers’s New Schizophrenia Med Flunks Phase 2 Test - 2 months ago ‘Serial Killing’ Cell Therapy From Autolus Lands FDA Approval in Blood Cancer - 2 months ago FDA Takes Step Toward Removal of Ineffective Decongestants From the Market - 2 months ago Private Equity Is Picking Up Biologics CDMO Avid Bioservices in $1.1B Acquisition - 3 months ago Acadia Pharma Sells Voucher for Speedier FDA Drug Review for $150M - 3 months ago Beam’s Base-Editing Sickle Cell Therapy Shows Early Promise, But a Fatality Overshadows Results - 3 months ago